Bluejay Diagnostics regains Nasdaq minimum bid price compliance; deficiency closed

Bluejay Diagnostics, Inc.

Received Nasdaq letter on Dec 3, 2024 confirming compliance with Rule 5550(a)(2).
Minimum bid price deficiency originally disclosed on March 4, 2024 is now closed.
Company's common stock (BJDX) remains listed on Nasdaq Capital Market.

item 8.01

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-105693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.